ACS Applied Materials & Interfaces · 2024 · 19 citations · 33 references
PharmacyImmunologyInfectious DiseasesGene DeliveryImmunizationVaccinologyMrna Vaccine TechnologyNucleic Acid VaccinesTherapeutic VaccinesVaccine Antigen DiscoveryVaccine DeliveryVaccine PlatformsLipid NanoparticlesMessenger Rna (Mrna) VaccinesMrna Delivery SystemsMrna Lipid NanoparticlesMultivalent VaccinesTherapeutic Vaccine EfficacyTrypanosoma Cruzi InfectionVaccine Candidate Antigens
Chagas disease (CD) (American trypanosomiasis caused by Trypanosoma cruzi ) is a parasitic disease endemic in 21 countries in South America, with increasing global spread. When administered late in the infection, the current antiparasitic drugs do not prevent the onset of cardiac illness leading to chronic Chagasic cardiomyopathy. Therefore, new therapeutic vaccines or immunotherapies are under development using multiple platforms. In this study, we assessed the feasibility of developing an mRNA-based therapeutic CD vaccine targeting two known T. cruzi vaccine antigens (Tc24─a flagellar antigen and ASP-2─an amastigote antigen). We present the mRNA engineering steps, preparation, and stability of the lipid nanoparticles and evaluation of their uptake by dendritic cells, as well as their biodistribution in c57BL/J mice. Furthermore, we assessed the immunogenicity and efficacy of two mRNA-based candidates as monovalent and bivalent vaccine strategies using an in vivo chronic mouse model of CD. Our results show several therapeutic benefits, including reductions in parasite burdens and cardiac inflammation, with each mRNA antigen, especially with the mRNA encoding Tc24, and Tc24 in combination with ASP-2. Therefore, our findings demonstrate the potential of mRNA-based vaccines as a therapeutic option for CD and highlight the opportunities for developing multivalent vaccines using this approach.
33
Manufacturing Considerations for the Development of Lipid Nanoparticles Using Microfluidics
Carla B. Roces, Gustavo Lou, Nikita Jain et al. · Pharmaceutics · 2020 · 302 citations · Full text
Role of nanotechnology behind the success of mRNA vaccines for COVID-19
Amit Khurana, Prince Allawadhi, Isha Khurana et al. · Nano Today · 2021 · 276 citations · Full text